$0.54
−1.57%Oct 8, 2026, 12:30 UTC
Nuwellis announced that it will convene a Medical & Nursing Advisory Board on November 18–19, 2026, to support development of its Vivian pediatric CRRT platform.
Source:Oct 1, 2026, 12:30 UTC
Nuwellis, Inc. announced its participation in four leading medical conferences in October 2026, where it will highlight its Aquadex SmartFlow system for fluid management in pediatric care, critical care, and heart failure.
Source:Sep 17, 2026, 12:30 UTC
Nuwellis reported that 31 Aquadex SmartFlow consoles were sold year-to-date, exceeding full-year console sales in seven of the past 10 years.
Source:Sep 16, 2026, 12:30 UTC
Nuwellis appointed Brian Johnson as Director of Quality and Regulatory Affairs.
Source:Aug 25, 2026, 12:30 UTC
Nuwellis entered into a strategic commercial agreement with Atrility Medical to expand its pediatric and critical care portfolio, with a milestone-based pathway to U.S. distribution.
Source:Aug 13, 2026, 12:00 UTC
Nuwellis, Inc. reported financial results for the three and six months ended June 30, 2026, highlighting double-digit revenue growth and expanded gross margin.
Source:Aug 6, 2026, 12:30 UTC
Nuwellis, Inc. announced the appointment of Dale Brady as Principal R&D Engineer on August 6, 2026.
Source:Aug 4, 2026, 12:30 UTC
Nuwellis announced a strategy to develop next-generation Aquadex platform capabilities for future critical care applications including immunomodulation and extracorporeal blood purification.
Source:Jul 31, 2026, 12:39 UTC
NUWELLIS announced the completion of a registered direct offering priced at market, raising $3.4 million, under Nasdaq rules.
Jul 31, 2026, 12:39 UTC
Nuwellis received $3.1 million from the exercise of previously issued warrants from the June 2026 public offering.
Source:Jul 16, 2026, 12:30 UTC
Nuwellis was awarded a U.S. patent for a novel catheter technology designed to enhance extracorporeal therapies.
Source:Jun 25, 2026, 12:30 UTC
Nuwellis, Inc. installed three Aquadex SmartFlow systems at a pediatric healthcare provider in Michigan, marking its first pediatric program in the state.
Jun 18, 2026, 00:00 UTC
John L. Erb resigned as Chief Executive Officer of Nuwellis, Inc., effective June 30, 2026, and Michael McCormick was appointed as his successor.
Jun 10, 2026, 12:30 UTC
Nuwellis expanded its collaboration with a major South Carolina healthcare system by installing new Aquadex SmartFlow devices at one of its children's hospitals and upgrading devices at two existing locations.
Source:Jun 9, 2026, 01:46 UTC
Nuwellis, Inc. closed a registered public offering of common stock and warrants, raising approximately $6.0 million in gross proceeds.
Jun 5, 2026, 12:30 UTC
Nuwellis, Inc. priced a public offering of 20,000,000 shares of common stock (or pre-funded warrants) with accompanying warrants for gross proceeds of approximately $6 million.
Source: